VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.45%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$3.44M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$670K |
| 2 |
Zai Lab
ZLAB
|
$520K |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$422K |
| 4 |
DRD
DRDGold
DRD
|
$405K |
| 5 |
Stellus Capital Investment Corp
SCM
|
$402K |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$1.28M |
| 2 |
Prothena Corp
PRTA
|
$971K |
| 3 |
BioNTech
BNTX
|
$787K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$647K |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$645K |
Sector Composition
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PHD
151
Pioneer Floating Rate Fund
PHD
$123M
| $499K | 0.21% |
41,845
+12,996
| +45% | +$155K |
|
152
United Therapeutics
UTHR
$17.6B
| $499K | 0.21% |
2,779
-1,597
| -36% | -$287K |
|
|
ONC
153
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.2B
| $497K | 0.2% |
1,448
-1,291
| -47% | -$443K |
|
154
Rigel Pharmaceuticals
RIGL
$721M
| $496K | 0.2% |
11,426
+2,229
| +24% | +$96.8K |
|
155
Neurocrine Biosciences
NBIX
$14.4B
| $488K | 0.2% |
5,012
-1,680
| -25% | -$164K |
|
156
Apellis Pharmaceuticals
APLS
$3.53B
| $486K | 0.2% |
7,693
+1,932
| +34% | +$122K |
|
157
BioCryst Pharmaceuticals
BCRX
$1.73B
| $485K | 0.2% |
30,669
-4,662
| -13% | -$73.7K |
|
158
Nektar Therapeutics
NKTR
$725M
| $485K | 0.2% |
1,883
-482
| -20% | -$124K |
|
|
RDUS
159
DELISTED
Radius Health, Inc.
RDUS
| $485K | 0.2% |
26,615
-15,921
| -37% | -$290K |
|
|
BHVN
160
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $483K | 0.2% |
4,973
-2,220
| -31% | -$216K |
|
161
PTC Therapeutics
PTCT
$4.6B
| $481K | 0.2% |
11,368
+1,892
| +20% | +$80.1K |
|
|
XLRN
162
DELISTED
Acceleron Pharma Inc.
XLRN
| $478K | 0.2% |
3,810
-1,000
| -21% | -$125K |
|
163
Omeros
OMER
$284M
| $477K | 0.2% |
32,130
-9,070
| -22% | -$135K |
|
|
ITCI
164
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $477K | 0.2% |
11,679
-13,085
| -53% | -$534K |
|
|
BLUE
165
DELISTED
bluebird bio
BLUE
| $476K | 0.2% |
1,150
+630
| +121% | +$261K |
|
166
Insmed
INSM
$30.3B
| $474K | 0.19% |
16,660
+982
| +6% | +$27.9K |
|
167
Agios Pharmaceuticals
AGIO
$2.15B
| $472K | 0.19% |
8,573
-9,755
| -53% | -$537K |
|
168
Travere Therapeutics
TVTX
$1.94B
| $471K | 0.19% |
32,254
+8,347
| +35% | +$122K |
|
|
EPZM
169
DELISTED
Epizyme, Inc
EPZM
| $471K | 0.19% |
56,674
+8,726
| +18% | +$72.5K |
|
170
Invesco Senior Income Trust
VVR
$553M
| $469K | 0.19% |
105,079
+32,846
| +45% | +$147K |
|
171
BlackRock Floating Rate Income Trust
BGT
$317M
| $468K | 0.19% |
36,418
+11,218
| +45% | +$144K |
|
|
ICPT
172
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $466K | 0.19% |
23,353
+3,978
| +21% | +$79.4K |
|
173
Y-mAbs Therapeutics
YMAB
$389M
| $464K | 0.19% |
13,728
+1,735
| +14% | +$58.6K |
|
|
EFR
174
Eaton Vance Senior Floating-Rate Fund
EFR
$344M
| $463K | 0.19% |
32,748
+8,419
| +35% | +$119K |
|
175
Ultragenyx Pharmaceutical
RARE
$3.09B
| $463K | 0.19% |
4,853
+766
| +19% | +$73.1K |
|